http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2635416-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-21 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-21 |
| filingDate | 2012-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21ad6f28aeec5451862bb664388a6c4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d586c64559bc298554d459194fb6043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9f4ae696783bab1e02b66f4cc53cb09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d755659279fe5f356d987be1f97045b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e866d895dbd60a3b423e20182047c7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_019e1be044f8ee83f8507bdfe7073599 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9976c303c2c3c1d989e0a0f9c1220db1 |
| publicationDate | 2017-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2635416-T3 |
| titleOfInvention | Exotoxin A from pseudomonas with epitopes of T lymphocytes and / or less immunogenic B lymphocytes |
| abstract | An exotoxin A of Pseudomonas (PE) comprising an amino acid sequence that has a substitution of one or more of the amino acid residues L294, L297, Y298, L299 and R302, with the proviso that when the amino acid sequence comprises a substitution of alanine for the remainder of amino acid R302, at least one of the amino acid residues L294, L297, Y298 and L299 is substituted, in which the amino acid residues L294, L297, Y298, L299 and R302 are defined by reference to SEQ ID NO: 1, and in which the PE exhibits an increase in cytotoxic activity and the PE exhibits a reduction in immunogenicity compared to an unsubstituted PE, optionally with a substitution of one or more of the residues of the amino acids within one or more B-cell epitopes of SEQ ID NO: 1 and / or a substitution of one or more of the amino acid residues within one or more T-cell epitopes within the amino acid residues R421, L422 , L 423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556 and W558 of SEQ ID NO: 1, preferably in which the replacement of one or more of the amino acid residues L294, L297, Y298, L299 and R302 is a substitution of alanine, glycine, serine or glutamine instead of one or more of the amino acid residues L294, L297, Y298, L299 and R302 |
| priorityDate | 2011-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 419.